question:The Gnifetti Hut (Italian: "Capanna Giovanni Gnifetti") is a refuge in the Alps in Aosta Valley, Italy. It is located at an altitude of 3647 m , and provides access to mountaineers climbing any of the fifteeen nearby 4,000 metre high summits of the Monte Rosa massif, and gives access to high-level glacier routes as well as to the Margherita Hut, located on the Signalkuppe. Based on that paragraph can we conclude that this sentence is true? The hut is located in Italy

question:Given the question: Answer the question based on the following text. Question: The sun has a weaker or stronger force of gravity than the moon? Text: Objects with greater mass have a stronger force of gravity. The answer is:

question:Matiç, profesyonel bir gazetecinin isminin önünde milliyetini belirten bir ekin olmaması gerektiği için, "Sırp gazetecilerden" veya Arnavut gazetecilerden" bahsetmenin gerekli olmadığını söyledi. Which language is this?

question:Definition: In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length. Input: The growth potential of the tumor-like Echinococcus multilocularis metacestode (causing alveolar echinococcosis, AE) is directly linked to the nature/function of the periparasitic host immune-mediated processes. We previously showed that Fibrinogen-like-protein 2 (FGL2), a novel CD4 + CD25 + Treg effector molecule, was over-expressed in the liver of mice experimentally infected with E. multilocularis. However, little is known about its contribution to the control of this chronic helminth infection. Key parameters for infection outcome in E. multilocularis-infected fgl2 -/-(AE-fgl2 -/-) and wild type (AE-WT) mice at 1 and 4 month(s) post-infection were (i) parasite load (i. e. wet weight of parasitic metacestode tissue), and (ii) parasite cell proliferation as assessed by determining E. multilocularis 14-3-3 gene expression levels. Serum FGL2 levels were measured by ELISA. Spleen cells cultured with ConA for 48h or with E. multilocularis Vesicle Fluid (VF) for 96h were analyzed ex-vivo and in-vitro. In addition, spleen cells from non-infected WT mice were cultured with rFGL2/anti-FGL2 or rIL-17A/anti-IL-17A for further functional studies. For Treg-immune-suppression-assays, purified CD4 + CD25 + Treg suspensions were incubated with CD4 + effector T cells in the presence of ConA and irradiated spleen cells as APCs. Flow cytometry and qRT-PCR were used to assess Treg, Th17-, Th1-, Th2-type immune PLOS Neglected Tropical Diseases | responses and maturation of dendritic cells. We showed that AE-fgl2 -/mice exhibited (as compared to AE-WT-animals) (a) a significantly lower parasite load with reduced proliferation activity, (b) an increased T cell proliferative response to ConA, (c) reduced Treg numbers and function, and (d) a persistent capacity of Th1 polarization and DC maturation. FGL2 appears as one of the key players in immune regulatory processes favoring metacestode survival by promoting Treg cell activity and IL-17A production that contributes to FGL2regulation. Prospectively, targeting FGL2 could be an option to develop an immunotherapy against AE and other chronic parasitic diseases. In larval E. multilocularis infection causing alveolar echinococcosis (AE) in humans as well as mice, immune tolerance and/or down-regulation of protective immunity is a marked characteristic of this chronic disease. Our study provides a comprehensive evidence for a major involvement of the recently identified CD4 + CD25 + Regulatory T Cell Effector Molecule FGL2 to the outcome of AE. Our major findings are as follows: 1) FGL2 is mostly secreted by Tregs and partly contributes to their functions; 2) FGL2 can downregulate the maturation of DCs, suppress Th1 and Th17 immune responses, and support Th2 and Treg immune responses, and finally 3) IL-17A contributes to FGL2 secretion. Based on the present findings in mice, we will investigate FGL2 as a potential marker of progression of AE in human patients, or as a potential immunotherapeutical target. Early prediction of parasite regression (currently not yet possible) would allow clinicians to plan for withdrawing benzimidazole treatment, which is currently administered for life. Then, FGL2 should be investigated as a target for an anticipated immunomodulatory treatment of patients with progressive AE, especially of those who are non-or low-responders to benzimidazole treatment, or who suffer from side-effects due to chemotherapy. FGL2 in Murine Alveolar Echinococcosis PLOS Neglected Tropical Diseases | Output: